



High-Cost Outlier Specialty Drug

Effective December 15, 2025, Medical Mutual requires that a unique reimbursement rate be agreed upon for certain high-cost specialty drugs. The provider can contact the network management contracting team to agree upon a reimbursement rate, which will be in line with one hundred percent (100%) of CMS or the wholesale acquisition cost (WAC) if there is no Medicare assigned rate. Unless there is an agreed upon reimbursement rate prior to claims submission, payment for these specialty drugs will be processed at one hundred percent (100%) of CMS or the wholesale acquisition cost (WAC) if there is no Medicare assigned rate.

The drugs listed below require a that a unique reimbursement rate be agreed upon for reimbursement:

HCPCS Code	Brand Name	Generic Name
Q2055	Abecma	idecabtagene vicleucel - Effective 1/1/2026 this drug will be included in the Optum Transplant Services and not subject to the High-Cost Outlier Specialty Drug process.
J9042	Adcetris	brentuximab vedotin
J9029	Adstiladrin	nadofaragene firadenovec-vncg
J7214	Altuviio	antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl
J9999/C9399	Amtagvi	Lifileucel - Effective 1/1/2026 this drug will be included in the Optum Transplant Services and not subject to the High-Cost Outlier Specialty Drug process.
J0225	Amvuttra	vutrisiran
J9028	Anktiva	nogapendekin alfa inbakicept-pmln
J1554	Asceniv	Immune Globulin (Human)
J9118	Asparlas	calaspargase pegol
Q2058	Aucatzyl	obecabtagene autoleucel - Effective 1/1/2026 this drug will be included in the Optum Transplant Services and not subject to the High-Cost Outlier Specialty Drug process.
J1414	Beqvez	fidanacogene elaparvovec-dzkt
J9030	Blinctyo	blinatumomab
Q2054	Breyanzi	lisocabtagene maraleucel - Effective 1/1/2026 this drug will be included in the Optum Transplant Services and not subject to the High-Cost Outlier Specialty Drug process.
Q2056	Carvykti	ciltacabtagene autoleucel - Effective 1/1/2026 this drug will be included in the Optum Transplant Services and not subject to the High-Cost Outlier Specialty Drug process.
J3392	Casgevy	exagamglogene autotemcel - Effective 1/1/2026 this drug will be included in the Optum Transplant Services and not subject to the High-Cost Outlier Specialty Drug process.
J9063	Elahere	mirvetuximab soravtansine-gynx
J1413	Elevidys	delandistrogene moxeparvovec-rokl

J3403	Encelto	revakinagene taroretcel-lwey
J9210	Gamifant	emapalumab-lzsg
J0223	Givlaari	givosiran
J1411	Hemgenix	etranacogene dezaparvovec
J9248	Hepzato	melphalan
J0638	Ilaris	canakinumab
J9347	Imjudo	tremelimumab-actl
J9325	Imlygic	talimogene laherparepvec
J9207	Ixemptra	ixabepilone
J9272	Jemperli	dostarlimab-gxly
J3590/C9399	Kebilidi	eladocogene exuparvovec-tneq
J9274	Kimmtrak	tebentafusp-tebn
Q2042	Kymriah	tisagenlecleucel-T - Effective 1/1/2026 this drug will be included in the Optum Transplant Services and not subject to the High-Cost Outlier Specialty Drug process.
J3590/C9399	Lantidra	donislecel
J3391	Lenmeldy	atidarsagene autotemcel - Effective 1/1/2026 this drug will be included in the Optum Transplant Services and not subject to the High-Cost Outlier Specialty Drug process.
A9513	Lutathera	lutetium Lu 177 dotatate
J3398	Luxturna	voretigene neparvovec
J3394	Lyfgenia	lovotibeglogene autotemcel - Effective 1/1/2026 this drug will be included in the Optum Transplant Services and not subject to the High-Cost Outlier Specialty Drug process.
J3590/C9399	Omisirge	omidubicel
J9266	Oncaspar	pegaspargase
J0222	Onpattro	patisiran
J9298	Opdualag	nivolumab and relatlimab-rmbw
J3590/C9399	Papzimeos	zopapogene imadenovect-drba
J9309	Polivy	polatuzumab vedotin-piiq
J9204	Poteligeo	mogamulizumab-kpkc
Q2043	Provenge	sipuleucel-T
J0896	Reblozyl	luspatercept-aamt
J3590/C9399	Rethymic	allogeneic processed thymus tissue-agdc
J1412	Roctavian	valoctocogene roxaparvovec
J9061	Rybrevant	amivantamab-vmjw
J9021	Rylaze	asparaginase erwinia chrysanthemi (recombinant)- rywn
J3402	Ryoncil	remestemcel-L-rknd
J3590/C9399	Skysona	elivaldogene autotemcel - Effective 1/1/2026 this drug will be included in the Optum Transplant Services and not subject to the High-Cost Outlier Specialty Drug process.
J1299	Soliris	eculizumab
J2326	Spinraza	nusinersen
J9226	Supprelin LA	Histrelin implant

Q2053	Tecartus	brexucabtagene autoleucel - Effective 1/1/2026 this drug will be included in the Optum Transplant Services and not subject to the High-Cost Outlier Specialty Drug process.
Q2057	Tecelra	afamitresgene autoleucel - Effective 1/1/2026 this drug will be included in the Optum Transplant Services and not subject to the High-Cost Outlier Specialty Drug process.
J3241	Tepezza	teprotumumab-trbw
J9273	Tivdak	tisotumab vedotin-tftv
J1303	Ultomiris	ravulizumab-cwvz
J1823	Uplinza	inebilizumab-cdon
J3401	Vyjuvek	beremagene geperpavec
J9332	Vyvgart	efgartigimod alfa-fcab
J9334	Vyvgart Hytrulo	efgartigimod alfa and hyaluronidase-qvfc
Q2041	Yescarta	axicabtagene ciloleucel - Effective 1/1/2026 this drug will be included in the Optum Transplant Services and not subject to the High-Cost Outlier Specialty Drug process.
J3590/C9399	Zevaskyn	prademagene zamikeracel - Effective 1/1/2026 this drug will be included in the Optum Transplant Services and not subject to the High-Cost Outlier Specialty Drug process.
J3399	Zolgensma	onasemnogene abeparvovec
J3393	Zynteglo	betibeglogene autotemcel - Effective 1/1/2026 this drug will be included in the Optum Transplant Services and not subject to the High-Cost Outlier Specialty Drug process.